stockrowWhat it does
Roivant Sciences is a biopharmaceutical company that develops medicines through subsidiaries it calls Vants. It acquires or licenses drug candidates, assigns their development to Vant teams and provides shared support and capital allocation. It also incubates discovery-stage companies and health technology startups that complement its medicines business.
Its pipeline is aimed at patients with autoimmune and inflammatory diseases and pulmonary hypertension, a condition involving high blood pressure in the lungs. Priovant is developing brepocitinib, an oral medicine that blocks signals involved in immune disease. Its application for dermatomyositis, a disease affecting the skin and muscles, is under review by the U.S. Food and Drug Administration (FDA). Priovant is also studying it for inflammatory eye disease and other skin conditions.
Immunovant is developing IMVT-1402, an antibody designed to reduce certain antibodies involved in autoimmune disease. Its programs include Graves’ disease, difficult-to-treat rheumatoid arthritis and other conditions. Pulmovant is studying mosliciguat, an inhaled medicine for pulmonary hypertension associated with interstitial lung disease.
Each Vant operates with its own management team and development mission. Roivant makes capital allocation decisions centrally, while Vant teams make operational decisions for their programs. The Vants can also use shared support functions and technology developed across the group.
All candidates in Roivant’s current pipeline are investigational and require health authority approval. Matthew Gline is chief executive officer.
How it makes money
Roivant’s revenue primarily comes from license agreements and subscription and service fees. Subscription and service-based revenue relates to the use of technology the company has developed. Roivant has a single reportable segment.
FY2026 revenue: $8.3 million. FY2025 revenue: $29.1 million.
Its drug candidates are investigational, so potential medicine sales depend on development, regulatory approval and commercialization. If approved, products developed under certain license agreements would generate sales subject to royalties and, in some cases, milestone payments to the licensors. Priovant’s brepocitinib agreement with Pfizer, for example, includes a sales milestone and tiered royalties on net sales. Immunovant’s anti-FcRn franchise and Pulmovant’s mosliciguat program also carry potential milestone and royalty obligations.
The company holds interests in its Vants and can realize proceeds through transactions involving those interests. Its ownership varies among subsidiaries, and other shareholders can participate in a Vant’s value. Roivant also retains rights to future milestones and royalties related to its sale of Dermavant.
Separate from revenue, Roivant recognized a litigation-settlement gain for Genevant’s expected portion of a fixed payment from Moderna to Genevant and Arbutus. That allocation is subject to adjustment for litigation costs, and an additional settlement payment depends on the outcome of an appeal. Roivant also earns interest on cash equivalents and marketable securities.
The subscription and service fees give Roivant a source of revenue from its technology business, alongside licensing arrangements. Future medicine sales would require the company to obtain approvals and establish commercial operations. Roivant expects to incur increased sales and marketing expenses if a candidate receives regulatory approval.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Reportable Segment | $29.1 million | — | — |
Customers and how it sells
Roivant’s investigational medicines are intended for patients with autoimmune and inflammatory conditions and pulmonary hypertension. Its programs address diseases affecting the skin and muscles, eyes, thyroid and nervous system, among other areas. Patients are not yet customers for medicines from the current pipeline: the candidates remain investigational and require health authority approval.
If products are approved, healthcare providers, physicians and third-party payors will play a role in enabling patient access. Roivant expects to build sales and marketing capabilities if a candidate receives regulatory approval. The company also earns subscription and service fees for the use of technology it has developed.
Roivant identifies U.S. patient populations for its programs. For brepocitinib, its estimates cover adults with dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris. For IMVT-1402, the company identifies patient populations with conditions including Graves’ disease, difficult-to-treat rheumatoid arthritis and Sjögren’s disease. These are disease-population estimates, not counts of Roivant customers.
Roivant conducts clinical development across different geographies, and its candidates are subject to health authority approval. The FDA is reviewing brepocitinib for dermatomyositis. Government authorities in the U.S. and other countries regulate drug research, development, approval and commercialization. Physicians and payors would help determine access to any products that receive approval.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Reportable Segment | $29.1 million | — | — |
Suppliers and costs
Research and development is central to Roivant’s cost structure. Program-specific expenses include payments to contract research and manufacturing organizations, materials for studies, consultants, investigator grants and sponsored research. Internal research costs include employee pay, benefits and share-based compensation.
Contract research organizations help conduct clinical trials, while contract manufacturers produce materials used in nonclinical and clinical studies. Roivant expects to enter additional research, manufacturing and supplier agreements, which may require upfront payments and longer-term commitments. Successful development also depends on the company or its manufacturing partners being able to make products successfully.
Roivant expects research and development expenses to increase as it advances candidates through studies and adds programs. It also expects general and administrative expenses to rise to support potential commercialization, including personnel and consultants. A product approval would lead to increased spending on sales and marketing capabilities.
Licensed programs carry contingent payment obligations. Immunovant may owe HanAll regulatory and sales milestones and tiered royalties on net sales for the anti-FcRn franchise. Pulmovant may owe Bayer development, regulatory and commercial milestones and royalties for mosliciguat. Priovant’s brepocitinib agreement with Pfizer also includes a sales milestone and royalties. These obligations depend on specified future events.
Costs of subscription and service-based revenue primarily comprise employees, hosting and third-party data.
- Revenue$8.3M
- Cost of revenue−$1.3M
- Research and development−$681.8M
- Selling, general and administrative−$610.5M
- Other operating costs−−$770.2M
- Operating income−$515.1M
Competitive position
Roivant expects competition from companies developing treatments for autoimmune diseases and pulmonary hypertension. Potential competitors to brepocitinib and IMVT-1402 include the FcRn blockers VYVGART and VYVGART Hytrulo. IMAAVY and RYSTIGGO are potential competitors to IMVT-1402; dazukibart is a potential competitor to brepocitinib. Tyvaso and Yutrepia are potential competitors to mosliciguat. Roivant’s candidates may also compete with medicines that work differently.
The companies behind those specific products are not identified in the competition discussion. Amgen and Merck are named in examples of acquisitions that expanded their respective rare-disease and cardiopulmonary portfolios; the discussion does not connect either company to a specific Roivant candidate.
Roivant’s model combines centralized capital allocation and shared support with Vant-level operating decisions. It also uses licensing relationships and computational tools in drug discovery, development and commercialization. Vant management teams focus on their own programs and receive Vant-specific equity incentives.
Competitive factors for an approved product include efficacy, safety, dosing convenience, price and reimbursement. Roivant also faces competition for clinical-trial participants. It says some competitors have greater resources and more experience obtaining approvals and commercializing medicines.
Our reading: The Vant structure and licensing network provide organizational capabilities, but their competitive strength depends on converting candidates into approved products. Our reading: The pipeline spans several diseases and drug types, although that breadth does not establish durable protection from competing treatments.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Amgen | Potential competition in rare-disease drug development | Medium |
| Merck | Potential competition in cardiopulmonary drug development | Medium |
Growth opportunities
Roivant plans to expand its pipeline through new in-licensing and to develop existing candidates across multiple diseases. For brepocitinib, the FDA has accepted Priovant’s dermatomyositis application for priority review. Priovant expects to launch the medicine following FDA approval.
The company expects topline data from a late-stage brepocitinib study in non-infectious uveitis and a mid-stage mosliciguat study in pulmonary hypertension associated with interstitial lung disease. It also expects cutaneous lupus data and further rheumatoid arthritis updates for IMVT-1402. Roivant expects later IMVT-1402 trial readouts in Graves’ disease, myasthenia gravis, Sjögren’s disease and chronic inflammatory demyelinating polyneuropathy.
Priovant is also pursuing brepocitinib in cutaneous sarcoidosis and lichen planopilaris. The FDA has granted brepocitinib Breakthrough Therapy Designation for cutaneous sarcoidosis. Roivant plans further development in that disease, while a potentially registrational trial is underway in lichen planopilaris.
Roivant sizes several potential U.S. patient populations for its programs, including people with difficult-to-treat rheumatoid arthritis and Sjögren’s disease. Those estimates do not establish how many patients would receive an approved Roivant medicine. The company also plans to use its in-licensing activities to add drug candidates to the pipeline.
Alongside drug development, Roivant retains an interest in Genevant and rights to future Dermavant-related milestones and royalties. The company believes its cash, cash equivalents and marketable securities support its cash runway into profitability. It also expects research and development expenses to increase as it advances and adds candidates.
- $55.3MFY2022
- $61.3MFY2023
- $32.7MFY2024
- $29.1MFY2025
- $8.3MFY2026
Bottom line
Our reading
Our reading: Roivant is primarily a drug-development business whose Vant structure spreads work across programs while keeping capital allocation at the parent. Its cash and portfolio provide resources to pursue several candidates, but future medicine sales depend on trial results, approvals and commercialization. The discontinued batoclimab program shows that setbacks can redirect spending even within a broader pipeline, while licensing obligations mean partners share in potential product proceeds.